Franklin Resources
CASC

Franklin Resources’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Franklin Resources’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,113,166
Closed -$4.61M – 1558
2017
Q1 		$4.61M Hold
1,113,166
– – ﹤0.01% 1120
2016
Q4 		$4.8M Sell
1,113,166
-36,767
-3% -$238K ﹤0.01% 1090
2016
Q3 		$11.3M Hold
1,149,933
– – 0.01% 953
2016
Q2 		$6.51M Hold
1,149,933
– – ﹤0.01% 1052
2016
Q1 		$8.76M Hold
1,149,933
– – ﹤0.01% 1008
2015
Q4 		$15.3M Hold
1,149,933
– – 0.01% 912
2015
Q3 		$18.9M Sell
1,149,933
-109,317
-9% -$2.24M 0.01% 859
2015
Q2 		$28.3M Buy
1,259,250
+17,533
+1% +$277K 0.01% 800
2015
Q1 		$12.1M Buy
1,241,717
+588,417
+90% +$5.77M 0.01% 1007
2014
Q4 		$7.45M Hold
653,300
– – ﹤0.01% 1106
2014
Q3 		$7.53M Sell
653,300
-92,800
-12% -$1.42M ﹤0.01% 1095
2014
Q2 		$14.5M Buy
746,100
+36,667
+5% +$647K 0.01% 964
2014
Q1 		$12.7M Buy
709,433
+411,366
+138% +$6.75M 0.01% 969
2013
Q4 		$3.15M Buy
+298,067
New +$3.33M ﹤0.01% 1214

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Franklin Resources's CASC Position: Q2 2017 in Review

Franklin Resources sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2017, closing a stake of 1,113,166 shares — an estimated $4.61M sold.

Franklin Resources first reported a position in CASC in Q4 2013 and held it in 14 quarters. The position peaked at $28.3M in Q2 2015. 76 funds tracked by Wall St. Rank hold CASC as of Q2 2017.

  • Franklin Resources reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Franklin Resources sold 1,113,166 Cascadian Therapeutics, Inc. shares in Q2 2017, an estimated $4.61M.
  • Franklin Resources first reported a position in Cascadian Therapeutics, Inc. in Q4 2013 and held it in 14 quarters.
  • Franklin Resources's Cascadian Therapeutics, Inc. position peaked at $28.3M in Q2 2015.
  • 76 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2017.

Based on Franklin Resources's 13F filing for Q2 2017, filed 10 Aug 2017.